Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

摘要: Abstract Context Gemcitabine for advanced pancreatic cancer (APC) is palliative and the prognosis poor, making health-related quality of life (HRQOL) particularly important. Objectives We evaluated HRQOL with EuroQol (EQ-5D™) in patients APC participating Cancer Leukemia Group B 80303, a multicenter, double-blind, randomized trial comparing overall survival (OS) between two treatment arms: gemcitabine bevacizumab or placebo. Methods A consecutive subsample was invited to complete EQ-5D surveys. Because neither clinical nor outcomes differed based on study arm, analyses were pooled. Changes mean scores from baseline eight weeks prognostic value evaluated. Results Mean index remained stable (0.78 at [n=267], 0.79 [n=186], P=0.34, Wilcoxon signed rank test), attributable modest deterioration physical function domain coincident small improvements pain anxiety/depression scores. decline visual analogue scale observed (70.7 vs. 68.2, P=0.026). changes within chemotherapy response strata revealed but trend worsened among disease progression compared those improved disease. Visual trended downward over time irrespective status, statistically meaningful who progressed (68.9 64.4, P=0.029). Baseline both scales significant predictors OS Cox proportional hazard models. Conclusion Response not associated appreciable improvement global HRQOL. Small mood are despite progressive functional decline. Those respond may experience slight slowing deterioration.